Chapter 02

  1. Abkowitz JL. 1991. Retrovirus-induced feline pure red blood cell aplasia: pathogenesis and response to suramin. Blood 77:1442-1451.
  2. Addie DD, Radford A, Yam PS, et al. 2003. Cessation of feline calicivirus shedding coincident with resolution of chronic gingivostomatitis in a cat. J Small Anim Pract 44:172-176.
  3. Arai M, Darman J, Lewis A, et al. 2000. The use of human hematopoietic growth factors (rhGM-CSF and rhEPO) as a supportive therapy for FIV-infected cats. Vet Immunol Immunopathol 77:71-92.
  4. Arai M, Earl DD, Yamamoto JK. 2002. Is AZT/3TC therapy effective against FIV infection or immunopathogenesis? Vet Immunol Immunopathol 85:189-204.
  5. Armstrong PJ. 1984. Systemic Serratia marcescens infections in a dog and a cat. J Am Vet Med Assoc 184:1154-1158.
  6. Bachman D, Cockerell GL, de Noronha F, et al. 1982. Effect of bacille Calmette-Guérin immunotherapy on feline sarcoma virus-induced neoplasms in the cat. Am J Vet Res 43:475-480.
  7. Balzarini J, Egberink H, Hartmann K, et al. 1996. Antiretrovirus specificity and intracellular metabolism of 2’,3’-didehydro-2’, 3’-dideoxythymidine (stavudine) and its 5’-monophosphate triester prodrug So324. Mol Pharmacol 50:1207-1213.
  8. Banos G, Daniel PM, Pratt OE. 1974. Saturation of a shared mechanism which transports L-arginine and L-lysine into the brain of the living rat. J Physiol 236:29-41.
  9. Barlough JE, Scott FW. 1990. Effectiveness of three antiviral agents against FIP virus in vitro. Vet Rec 126:556-558.
  10. Becker AM, Janik TA, Smith EK, et al. 1989. Propionibacterium acnes immunotherapy in chronic recurrent canine pyoderma. An adjunct to antibiotic therapy. J Vet Intern Med 3:26-30.
  11. Bertens AP. 1979. Passive and active immunization against feline enteritis and rhinotracheitis in experimental cats. Tijdschr Diergeneeskd 104:107-110.
  12. Bisset LR, Lutz H, Boni J, et al. 2002. Combined effect of zidovudine (ZDV), lamivudine (3TC) and abacavir (ABC) antiretroviral therapy in suppressing in vitro FIV replication. Antiviral Res 53:35-45.
  13. Bleul CC, Wu L, Hoxie JA, et al. 1997. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci USA 94:1925-1930.
  14. Bowles CA, Messerschmidt G, Deisseroth AB. 1984. Experience with Staphylococcus aureus and protein A in the treatment of canine malignancies. J Biol Response Mod 3:260-265.
  15. Bunch SE. 1993. Hepatotoxicity associated with pharmacologic agents in dogs and cats. Vet Clin North Am Small Anim Pract 23:659-670.
  16. Calvert CA. 1998. Canine viral papillomatosis, pp 49-51. In Greene CE (ed): Infectious diseases of the dog and cat, ed 2. WB Saunders, Philadelphia.
  17. Cantell K, Pyhala L. 1973. Circulating interferon in rabbits after administration of human interferon by different routes. J Gen Virol 20:97-104.
  18. Carmichael LE, Greene CE. 1998. Canine herpesvirus infection, pp 28-32. In Greene CE (ed): Infectious diseases of the dog and cat, ed 2. WB Saunders, Philadelphia.
  19. Cocker FM, Howard PE, Harbour DA. 1987. Effect of human alpha-hybrid interferon on the course of feline viral rhinotracheitis. Vet Rec 120:391-393.
  20. Cogan DC, Cotter SM, Kitchen LW. 1986. Effect of suramin on serum viral replication in feline leukemia virus-infected pet cats. Am J Vet Res 47:2230-2232.
  21. Cohn LA, Rewerts JM, McCaw D, et al. 1999. Plasma granulocyte colony-stimulating factor concentrations in neutropenic, parvoviral enteritis-infected puppies. J Vet Intern Med 13:581-586.
  22. Collins P. 1983. The spectrum of antiviral activities of acyclovir in vitro and in vivo. J Antimicrob Chemother 12:19-27.
  23. Cotter SM. 1991. Management of healthy feline leukemia virus-positive cats. J Am Vet Med Assoc 199:1470-1473.
  24. Cowgill LD. 1995. CVT update: use of recombinant human erythropoietin, pp 961-963. In Bonagura JD (ed): Kirk's current veterinary therapy XII small animal practice. WB Saunders, Philadelphia.
  25. Cummins JM, Beilharz MW, Krakowka S. 1999. Oral use of interferon. J Interferon Cytokine Res 19:853-858.
  26. Cummins JM, Tompkins MB, Olsen RG, et al. 1988. Oral use of human alpha interferon in cats. J Biol Response Mod 7:513-523.
  27. Day NK, Engelman RW, Liu WT, et al. 1984. Remission of lymphoma leukemia in cats following ex vivo immunosorption therapy using Staphylococcus protein A. J Biol Response Mod 3:278-285.
  28. De Clercq E. 1979. Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses. Cancer Lett 8:9-22.
  29. De Clercq E. 1982. Comparative efficacy of antiherpes drugs in different cell lines. Antimicrob Agents Chemother 21:661-663.
  30. De Mari K, Maynard L, Eun HM, et al. 2003. Treatment of canine parvoviral enteritis with interferon-omega in a placebo-controlled field trial. Vet Rec 152:105-108.
  31. deMari K, Maynard L, Sanquer A, et al. 2004. Therapeutic effects of recombinant feline interferon-ω on feline leukemia virus (FeLV)-infected and FeLV-feline immunodeficiency virus (FIV) co-infected cats. J Vet Intern Med 18:477-482.
  32. Dillon R. 1984. Feline dirofilariasis. Vet Clin North Am Small Anim Pract 14:1185-1199.
  33. Donzella GA, Schols D, Lin SW, et al. 1998. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 4:72-77.
  34. Egberink HF, De Clercq E, Van Vliet AL, et al. 1999. Bicyclams, selective antagonists of the human chemokine receptor CXCR4, potently inhibit feline immunodeficiency virus replication. J Virol 73:6346-6352.
  35. Egberink HF, Hartman K, Horzinek MC. 1991. Chemotherapy of feline immunodeficiency virus infection. J Am Vet Med Assoc 199:1485-1487.
  36. Elia G, Belloli C, Cirone F, et al. 2008. In vitro efficacy of ribavirin against canine distemper virus. Antiviral Res 77:108-113.
  37. Elmslie RE, Ogilvie GK, Dow SW, et al. 1991. Evaluation of a biologic response modifier derived from Serratia marcescens: effects on feline macrophages and usefulness for the prevention and treatment of viremia in feline leukemia virus-infected cats. Mol Biother 3:231-238.
  38. Engelman RW, Tyler RD, Trang LQ, et al. 1985. Clinicopathologic responses in cats with feline leukemia virus-associated leukemia-lymphoma treated with staphylococcal protein A. Am J Pathol 118:367-378.
  39. Erhardt W. 1977. Use of passive and active vaccines against panleukopenia in cats. Berl Munch Tierarztl Wochenschr 90:337-340
  40. Ferszt R, Kuhl KP, Bode L, et al. 1999. Amantadine revisited: an open trial of amantadine sulfate treatment in chronically depressed patients with Borna disease virus infection. Pharmacopsychiatry 32:142-147.
  41. Fogleman RW, Chapdelaine JM, Carpenter RH, et al. 1992. Toxicologic evaluation of injectable acemannan in the mouse, rat and dog. Vet Hum Toxicol 34:201-205.
  42. Fontenelle JP, Powell CC, Veir JK, et al. 2008. Effect of topical ophthalmic application of cidofovir on experimentally induced primary ocular feline herpesvirus-1 infection in cats. Am J Vet Res 69:289-293.
  43. Fox LM, Bruederle JB. 1996. Nearly foolproof parvovirus treatments. Vet Forum 13:36-38.
  44. Fulton RW, Burge LJ. 1985. Susceptibility of feline herpesvirus 1 and a feline calicivirus to feline interferon and recombinant human leukocyte interferons. Antimicrob Agents Chemother 28:698-699.
  45. Gobert JM, Remington KM, Zhu YQ, et al. 1994. Multiple-drug-resistant mutants of feline immunodeficiency virus selected with 2’,3’-dideoxyinosine alone and in combination with 3’-azido-3’-deoxythymidine. Antimicrob Agents Chemother 38:861-864.
  46. Govorkova EA, Ilyushina NA, Boltz DA, et al. 2007. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob Agents Chemother 51: 1414-1424.
  47. Greene CE. 1990. Antiviral chemotherapy, pp 221-225. In Greene CE (ed): Infectious diseases of the dog and cat. WB Saunders, Philadelphia.
  48. Greene CE. 1998. Hantavirus infection, pp 111-112. In Greene CE (ed): Infectious diseases of the dog and cat, ed 2. WB Saunders, Philadelphia.
  49. Greene CE. 1998. Immunoprophylaxis and immunotherapy, pp 717-750. In Greene CE (ed): Infectious diseases of the dog and cat, ed 2. WB Saunders, Philadelphia.
  50. Greene CE, Watson ADJ. 1998. Antiviral drugs, pp 6-9. In Greene CE (ed): Infectious diseases of the dog and cat, ed 2. WB Saunders, Philadelphia.
  51. Greene CE, Watson ADJ. 1998. Antimicrobial drug formulary, pp 790-919. In Greene CE (ed): Infectious diseases of the dog and cat, ed 2. WB Saunders, Philadelphia.
  52. Gregory CR, Barlough JE, Clark R, et al. 1997. Effects of insulin-like growth factor-1 and AZT in cats experimentally infected with FIV. Feline Pract 25:23-31.
  53. Griffith RS, DeLong DC, Nelson JD. 1981. Relation of arginine-lysine antagonism to herpes simplex growth in tissue culture. Chemotherapy 27:209-213.
  54. Griffith RS, Norins AL, Kagan C. 1978. Multicentered study of lysine therapy in Herpes simplex infection. Dermatologica 156:257-267.
  55. Haid C, Kaps S, Gönczi E, et al. 2007. Pretreatment with feline interferon omega and the course of subsequent infection with feline herpesvirus in cats. Vet Ophthalmol 10:278-284.
  56. Hallensleben W, Zocher M, Staeheli P. 1997. Borna disease virus is not sensitive to amantadine. Arch Virol 142:2043-2048.
  57. Harder TC, Findik A, Nolte I, et al. 1994. Untersuchungen zum Spektrum viraler Erreger im Rahmen des Katzenschnupfenkomplexes. Therapieversuche mit dem Herpesvirustatikum Azyklovir (Zovirax). Kleintierprax 39:93-106.
  58. Harper HD, Sjoquist J, Hardy WD Jr, et al. 1985. Antitumor activity of protein A administered intravenously to pet cats with leukemia or lymphosarcoma. Cancer 55:1863-1867.
  59. Harris C, Pierce K, King G, et al. 1991. Efficacy of acemannan in treatment of canine and feline spontaneous neoplasms. Mol Biother 3:207-213.
  60. Hart S, Nolte I. 1995. Long term treatment of diseased FIV-seropositive field cats with azidothymidine. Zentrabl Veterinarmed A 42:397-409.
  61. Hartmann K. 1995. AZT in the treatment of feline immunodeficiency virus infection: part 1. Feline Pract 23:16-21.
  62. Hartmann K. 1995. AZT in the treatment of feline immunodeficiency virus infection: part 2. Feline Pract 23:13-20.
  63. Hartmann K. 1998. Feline immunodeficiency virus infection. Brit Vet J 155:123-137.
  64. Hartmann K, Block A, Ferk G, et al. 1998. Treatment of feline leukemia virus-infected cats with paramunity inducer. Vet Immunol Immunopathol 65:267-275.
  65. Hartmann K, Block A, Ferk G, et al. 1999. Treatment of feline leukemia virus (FeLV) infection. Vet Microbiol 69:111-113.
  66. Hartmann K, Brunner K, Lutz H. 2002. Treatment of feline leukemia virus infection with 3-azido-2,3-dideoxythymidine and human alpha-interferon, p 799. In Proceedings of the 20th Annual Conference, American College of Veterinary Internal Medicine, Dallas, May, 2002.
  67. Haschek WM, Weigel RM, Scherba G, et al. 1990. Zidovudine toxicity to cats infected with feline leukemia virus. Fundam Appl Toxicol 14:764-775.
  68. Hayes KA, Lafrado LJ, Erickson JG, et al. 1993. Prophylactic ZDV therapy prevents early viremia and lymphocyte decline but not primary infection in feline immunodeficiency virus-inoculated cats. J Acquir Immune Defic Syndr 6:127-134.
  69. Hess PW. 1977. Principles of cancer chemotherapy. Vet Clin North Am 7:21-33.
  70. Hirschberger J. 1988. Administration of acyclovir (virustatic) to cats. Tierarztl Prax 16:427-430.
  71. Hoover EA, Zeidner NS, Perigo NA, et al. 1989. Feline leukemia virus-induced immunodeficiency syndrome in cats as a model for evaluation of antiretroviral therapy. Intervirology 30:12-25.
  72. Hörber D, Mayr B. 1991. Paramunization of FeLV-positive cats with PIND-AVI. Tierarztl Prax 19:311-313.
  73. Howard OM, Korte T, Tarasova NI, et al. 1998. Small molecule inhibitor of HIV-1 cell fusion blocks chemokine receptor-mediated function. J Leukoc Biol 64:6-13.
  74. Hsu WH. 1980. Toxicity and drug interactions of levamisole. J Am Vet Med Assoc 176:1166-1169.
  75. Hurt AC, Selleck P, Komadina N, et al. 2007. Susceptibility of highly pathogenic A (H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res 73: 228-231.
  76. Hussein IT, Field HJ. 2008. Development of a quantitative real-time TaqMan PCR assay for testing the susceptibility of feline herpesvirus-1 to antiviral compounds. J Virol Methods 152:85-90.
  77. Hussein IT, Menashy RV, Field HJ. 2008. Penciclovir is a potent inhibitor of feline herpesvirus-1 with susceptibility determined at the level of virus-encoded thymidine kinase. Antiviral Res 78:268-274.
  78. Ishida T, Shibanai A, Tanaka S, et al. 2002. Recombinant feline interferon therapy of feline infectious peritonitis, p 15. In Proceedings of the 2nd International FCoV/FIP Symposium, Aug 4-7, Glasgow, Scotland.
  79. Ishiwata K, Minagawa T, Kajimoto T. 1998. Clinical effects of the recombinant feline interferon-omega on experimental parvovirus infection in beagle dogs. J Vet Med Sci 60:911-917.
  80. Jameson P, Essex M. 1983. Inhibition of feline leukemia virus replication by human leukocyte interferon. Antiviral Res 3:115-120.
  81. Jones FR, Grant CK, Snyder HW Jr. 1984. Lymphosarcoma and persistent feline leukemia virus infection of pet cats: a system to study responses during extracorporeal treatments. J Biol Response Mod 3:286-292.
  82. Jordan HL, Pereira AS, Cohen MS, et al. 2001. Domestic cat model for predicting human nucleoside analogue pharmacokinetics in blood and seminal plasma. Antimicrob Agents Chemother 45:2173-2176.
  83. Kaplan AS, Shimono H, Ben-Porat T. 1970. Synthesis of proteins in cells infected with herpesvirus. 3. Relative amino acid content of various proteins formed after infection. Virology 40:90-101.
  84. Kimes AS, Kumor K, McCullough K, et al. 1989. Effects of acute and chronic acyclovir on canine renal function. J Pharmacol Exp Ther 249:483-491.
  85. King GK, Yates KM, Greenlee PG, et al. 1995. The effect of Acemannan Immunostimulant in combination with surgery and radiation therapy on spontaneous canine and feline fibrosarcomas. J Am Anim Hosp Assoc 31:439-447.
  86. Kitchen LW, Mather FJ. 1989. Hematologic effects of short-term oral diethylcarbamazine treatment given to chronically feline leukemia virus-infected cats. Cancer Lett 45:183-187.
  87. Kitchen LW, Mather FJ, Cotter SM. 1988. Effect of continuous oral diethylcarbamazine treatment on lymphocyte counts of feline leukemia virus-infected cats. J Clin Lab Immunol 27:179-181.
  88. Klausner JS, Miller WJ, O’Brien TD, et al. 1985. Effects of plasma treatment with purified protein A and Staphylococcus aureus Cowan I on spontaneous animal neoplasms. Cancer Res 45:1263-1269.
  89. Koech DK, Obel AO. 1990. Efficacy of Kemron (low dose oral natural human interferon alpha) in the management of HIV-1 infection and acquired immune deficiency syndrome (AIDS). East Afr Med J 67:64-70.
  90. Kraft W, Kuffer M. 1995. Treatment of severe neutropenias in dogs and cats with filgrastim. Tierarztl Prax 23:609-613.
  91. Lafrado JL, Mathes LE, Zack PM, et al. 1990. Biological effects of staphylococcal protein A immunotherapy in cats with induced feline leukemia virus infection. Am J Vet Res 51:482-486.
  92. Ledbetter EC, Riis RC, Kern TJ, et al. 2006. Corneal ulceration associated with naturally occurring canine herpesvirus-1 infection in two adult dogs. J Am Vet Med Assoc 229:376-384.
  93. Lee BJ, Matsunaga H, Ikuta K, et al. 2008. Ribavirin inhibits Borna disease virus proliferation and fatal neurological diseases in neonatally infected gerbils. Antiviral Res 80:380-384.
  94. Legendre AM, Bartges JW. 2009. Effect of Polyprenyl Immunostimulant on the survival times of three cats with the dry form of feline infectious peritonitis. J Feline Med Surg 11:624-626.
  95. Leifer CE, Page RL, Matus RE, et al. 1987. Proliferative glomerulonephritis and chronic active hepatitis with cirrhosis associated with Corynebacterium parvum immunotherapy in a dog. J Am Vet Med Assoc 190:78-80.
  96. Leneva IA, Roberts N, Govorkova EA, et al. 2000. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res 48:101-105.
  97. Levy JK. 2000. FeLV and non-neoplastic FeLV-related disease, pp 424-432. In Ettinger SJ, Feldman EC (ed): Textbook of veterinary internal medicine. WB Saunders, Philadelphia.
  98. Levy JK, Crawford PC. 2000. Failure of passive transfer in neonatal kittens: correction by administration of adult cat serum. J Vet Intern Med 14:362.
  99. Lies M. 1990. Volume of opinion warrants merit. Vet Forum 6:42.
  100. Liles WC, Broxmeyer HE, Rodger E, et al. 2003. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 102:2728-2730.
  101. Liu WT, Engelman RW, Trang LQ, et al. 1984. Appearance of cytotoxic antibody to viral gp70 on feline lymphoma cells (FL-74) in cats during ex vivo immunoadsorption therapy: quantitation, characterization, and association with remission of disease and disappearance of viremia. Proc Natl Acad Sci USA 81:3516-3520.
  102. Liu WT, Good RA, Trang LQ, et al. 1984. Remission of leukemia and loss of feline leukemia virus in cats injected with Staphylococcus protein A: association with increased circulating interferon and complement-dependent cytotoxic antibody. Proc Natl Acad Sci USA 81:6471-6475.
  103. Lockhart A, Ray JD, Barbee JS. 1925. Immunity against canine distemper. A report of the development of a new immunizing agent of high efficacy. J Am Vet Med Assoc 67:668-670.
  104. London C. 2000. Hematopoietic cytokines: the myelopoietic factors, pp 403-408. In Bonagura JD (ed): Kirk's current veterinary therapy XIII small animal practice. WB Saunders, Philadelphia.
  105. Ludwig H, Bode L. 2000. Borna disease virus: new aspects on infection, disease, diagnosis and epidemiology. Rev Sci Tech 19:259-288.
  106. Lvov ND, Chekanovskaya LA, Alimbarova LM, et al. 1995. Antiviral activity of vegetan, a new natural immunostimulator, in herpetic meningoencephalitis of mice, genital herpes of guinea pigs and parvoviral enteritis of dogs. Vopr Virusol 40:85-89.
  107. MacEwen EG. 1977. An immunologic approach to the treatment of cancer. Vet Clin North Am 7:65-75.
  108. MacEwen EG, Hayes AA, Mooney S, et al. 1984. Evaluation of effect of levamisole on feline mammary cancer. J Biol Response Mod 3:541-546.
  109. MacEwen EG, Patnaik AK, Harvey HJ, et al. 1986. Canine oral melanoma: comparison of surgery versus surgery plus Corynebacterium parvum. Cancer Invest 4:397-402.
  110. Macintire DK, Smith-Carr S, Jones R, et al. 1999. Treatment of dogs naturally infected with canine parvovirus with lyophilized canine IgG, abstract #118, p 721. In Proceedings of the 17th Annual Conference, American College of Veterinary Internal Medicine, Jun 10–13, Chicago.
  111. Macy DW. 1995. Use of antiviral agents in cats. Feline Pract 23(5):25-26.
  112. Maggs DJ, Clarke HE. 2004. In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1. Am J Vet Res 65:399-403.
  113. Maggs DJ, Collins BK, Thorne JG, et al. 2000. Effects of L-lysine and L-arginine on in vitro replication of feline herpesvirus type-1. Am J Vet Res 61:1474-1478.
  114. Maggs DJ, Nasisse MP, Kass PH. 2003. Efficacy of oral supplementation with L-lysine in cats latently infected with feline herpesvirus. Am J Vet Res 64:37-42.
  115. Martin CL, Stiles J. 1998. Ocular Infections, pp 658-672. In Greene CE (ed): Infectious diseases of the dog and cat, ed 2. WB Saunders, Philadelphia.
  116. Martin V, Najbar W, Gueguen S, et al. 2002. Treatment of canine parvoviral enteritis with interferon-omega in a placebo-controlled challenge trial. Vet Microbiol 89:115-127.
  117. Mathes LE, Hayes KA, Swenson CL, et al. 1994. Evaluation of antiviral activity and toxicity of dextran sulfate in feline leukemia virus-infected cats. Antimicrob Agents Chemother 35:2147-2150.
  118. Mayer P, Werner FJ, Lam C, et al. 1990. In vitro and in vivo activity of human recombinant granulocyte-macrophage colony-stimulating factor in dogs. Exp Hematol 18:1026-1033.
  119. Maynard L, De Mari K, Lebreux B. 2000. Efficacy of a recombinant feline omega interferon in the treatment of symptomatic FeLV- or FeLV- and FIV-positive cats, p 122a. In Proceedings of the 10th Congress, European Society of Veterinary InternalMedicine, Sep 14–16, Neuchâtel, Switzerland.
  120. Mayr A, Büttner M. 1984. New insights into the foundations of paramunity and paramunization. Berl Munch Tierarztl Wochenschr 97:429-435.
  121. McCaw DL, Boon GD, Jergens AE, et al. 2001. Immunomodulation therapy for feline leukemia virus infection. J Am Anim Hosp Assoc 37:356-363.
  122. Medlin HK, Zhu YQ, Remington KM, et al. 1996. Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2’,3’-dideoxycytidine. Antimicrob Agents Chemother 40:953-957.
  123. Megid J, Kaneno R. 2000. Natural killer activity in mice infected with rabies virus and submitted to P. acnes (Propionibacterium acnes) as immunomodulator. Comp Immunol Microbiol Infect Dis 23:91-97.
  124. Meuer SC, Dumann H, Buschenfelde KM, et al. 1989. Low dose interleukin-2 induces systemic immune responses against HBs Ag in immunodeficient non-responders to hepatitis B vaccination. Lancet 1:15-17.
  125. Meunier PC, Cooper BJ, Appel MJ, et al. 1985. Pathogenesis of canine parvovirus enteritis: sequential virus distribution and passive immunization studies. Vet Pathol 22:617-624.
  126. Mihaljevic SY. 2003. First clinical experiences with omega-interferon in the treatment of chronic gingivitis-stomatitis-oropharyngitis of cats. Der Prakt Tierarzt 84:350-361.
  127. Minagawa T, Ishiwata K, Kajimoto T. 1999. Feline interferon-omega treatment on canine parvovirus infection. Vet Microbiol 69:51-53.
  128. Mischke R, Barth T, Wohlsein P, et al. 2001. Effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on leukocyte count and survival rate of dogs with parvoviral enteritis. Res Vet Sci 70:221-225.
  129. Mizutani T, Inagaki H, Araki K, et al. 1998. Inhibition of Borna disease virus replication by ribavirin in persistently infected cells. Arch Virol 143:2039-2044.
  130. Mochizuki M, Nakatani H, Yoshida M. 1994. Inhibitory effects of recombinant feline interferon on the replication of feline enteropathogenic viruses in vitro. Vet Microbiol 39:145-152.
  131. Nasisse MP, Guy JS. 1989. Feline ocular disease and rhinotracheitis virus. Vet Med Rep 1:155-165.
  132. Nasisse MP, Guy JS, Davidson MG, et al. 1989. In vitro susceptibility of feline herpesvirus-1 to vidarabine, idoxuridine, trifluridine, acyclovir, or bromovinyldeoxyuridine. Am J Vet Res 50:158-160.
  133. Nasisse MP, Dorman DC, Jamison KC, et al. 1997. Effects of valacyclovir in cats infected with feline herpesvirus 1. Am J Vet Res 58:1141-1144.
  134. National Poison Control Center. 2009. http://www.aspca.org/pet-care/poison-control/. Accessed 9/2/09.
  135. Nelson P, Sellon R, Novotney C, et al. 1995. Therapeutic effects of diethylcarbamazine and 3’-azido-3’-deoxythymidine on feline leukemia virus lymphoma formation. Vet Immunol Immunopathol 46:181-194.
  136. Ogilvie GK. 1995. Hematopoietic growth factors: frontiers for cure. Vet Clin North Am Small Anim Pract 25:1441-1456
  137. Ogilvie GK, Elmslie RE, Cecchini M, et al. 1992. Use of a biological extract of Serratia marcescens to decrease doxorubicin-induced myelosuppression in dogs. Am J Vet Res 53:1787-1790.
  138. Owens JG, Nasisse MP, Tadepalli SM, et al. 1996. Pharmacokinetics of acyclovir in the cat. J Vet Pharmacol Ther 19:488-490.
  139. Paltrinieri S, Crippa A, Comerio T, et al. 2007. Evaluation of inflammation and immunity in cats with spontaneous parvovirus infection: consequences of recombinant feline interferon-omega administration. Vet Immunol Immunopathol 118:68-74.
  140. Peacock GV. 1996. Agents for passive immunization against canine distemper. J Am Vet Med Assoc 149:633-636.
  141. Pedretti E, Passeri B, Amadori M, et al. 2006. Low-dose interferon-alpha treatment for feline immunodeficiency virus infection. Vet Immunol Immunopathol 109:245-254.
  142. Polas PJ, Swenson CL, Sams R, et al. 1990. In vitro and in vivo evidence that the antiviral activity of 2’,3’-dideoxycytidine is target cell dependent in a feline retrovirus animal model. Antimicrob Agents Chemother 34:1414-1421.
  143. Povey RC. 1978. Effect of orally administered ribavirin on experimental feline calicivirus infection in cats. Am J Vet Res 39:1337-1341.
  144. Povey RC. 1978. In vitro antiviral efficacy of ribavirin against feline calicivirus, feline viral rhinotracheitis virus, and canine parainfluenza virus. Am J Vet Res 39:175-178.
  145. Priosoeryanto BP, Tateyama S, Yamaguchi R, et al. 1995. Antiproliferation and colony-forming inhibition activities of recombinant feline interferon (rFeIFN) on various cells in vitro. Can J Vet Res 59:67-69.
  146. Reinemeyer CR, Faulkner CT, Assadi-Rad AM, et al. 1995. Comparison of the efficacies of three heartworm preventives against experimentally induced infections with Ancylostoma caninum and Toxocara canis in pups. J Am Vet Med Assoc 206:1710-1715.
  147. Remington KM, Chesebro B, Wehrly K, et al. 1991. Mutants of feline immunodeficiency virus resistant to 3’-azido-3’-deoxythymidine. J Virol 65:308-312.
  148. Rewerts JM, McCaw DL, Cohn LA, et al. 1998. Recombinant human granulocyte colony-stimulating factor for treatment of puppies with neutropenia secondary to canine parvovirus infection. J Am Vet Med Assoc 213:991-992.
  149. Richardson JA. 2000. Accidental ingestion of acyclovir in dogs: 105 reports. Vet Hum Toxicol 42:370-371.
  150. Ritschel WA, Grummich KW, Hussain SA. 1985. Pharmacokinetics of PFA (trisodium phosphonoformate) after IV and PO administration to beagle dogs and rabbits. Methods Find Exp Clin Pharmacol 7:41-48.
  151. Ritz S, Egberink H, Hartmann K. 2007. Effect of feline interferon-omega on the survival time and quality of life of cats with feline infectious peritonitis. J Vet Intern Med 21:1193-1197.
  152. Rogers R, Merigan TC, Hardy WD Jr, et al. 1972. Cat interferon inhibits feline leukemia virus infection in cell culture. Nat New Biol 237:270-271.
  153. Rollinson EA. 1988. Prospects for the development of antiviral agents for veterinary use, pp 85-117. In Field HJ (ed): Antiviral agents: the development and assessment of antiviral chemotherapy, vol 2. CRC Press, Boca Raton, FL.
  154. Rucker J, Edinger AL, Sharron M, et al. 1997. Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. J Virol 71:8999-9007.
  155. Ryrfeldt A, Nordgren T, Lundstrom J. 1992. Hypocalcemia induced by foscarnet (Foscavir) infusion in dogs. Fundam Appl Toxicol 18:126-130.
  156. Sandmeyer LS, Keller CB, Bienzle D. 2005. Effects of cidofovir on cell death and replication of feline herpesvirus-1 cultured in epithelial cells. Am J Vet Res 66:217-722.
  157. Sato R, Inanami O, Tanaka Y, et al. 1996. Oral administration of bovine lactoferrin for treatment of intractable stomatitis in feline immunodeficiency virus (FIV)-positive and FIV-negative cats. Am J Vet Res 57:1443-1446.
  158. Schellekens H, Geelen G, Meritet J-F, et al. 2001. Oromucosal interferon therapy: relationship between antiviral activity and viral load. J Interferon Cytokine Res 21:575-581.
  159. Schols D, Struyf S, Van Damme J, et al. 1997. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 186:1383-1388.
  160. Sheets MA, Unger BA, Giggleman GF Jr, et al. 1991. Studies of the effect of acemannan on retrovirus infections: clinical stabilization of feline leukemia virus-infected cats. Mol Biother 3:41-45.
  161. Siebeck N, Hurley DJ, Garcia M, et al. 2006. Effects of human recombinant alpha-2b interferon and feline recombinant omega interferon on in vitro replication of feline herpesvirus-1. Am J Vet Res 67:1406-1411.
  162. 161a. Smith AW, Iversen PL, O’Hanley PD, et al. 2008. Virus-specific antiviral treatment fo controlling severe and fatal outbreaks of feline calicivirus infection. Am J Vet Res 69:23-32.
  163. Smith JS, Yager PA, Baer GM. 1980. Minimal interferon induction in dogs, using a modified polyriboinosinic-polyribocytidylic acid complex. Am J Vet Res 41:1833-1835.
  164. Smith RA, Remington KM, Preston BD, et al. 1998. A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (−)-beta-2’,3’-dideoxy-3’-thiacytidine and 3’-azido-3’-deoxythymidine. J Virol 72:2335-2340.
  165. Smyth NR, Bennett M, Gaskell RM, et al. 1994. Effect of 3’azido-2’,3’-deoxythymidine (AZT) on experimental feline immunodeficiency virus infection in domestic cats. Res Vet Sci 57:220-224.
  166. Smyth NR, McCracken C, Gaskell RM, et al. 1994. Susceptibility in cell culture of feline immunodeficiency virus to eighteen antiviral agents. J Antimicrob Chemother 34:589-594.
  167. Snyder HW Jr, Ernst NR, Grosmaire LS, et al. 1987. Selective removal of antigen-complexed IgG from cat plasma by adsorption onto a protein A–silica matrix. J Immunol Methods 101:209-217.
  168. Steed VP. 1987. Improved survival of four cats infected with feline leukemia virus after oral administration of interferon. Feline Pract 17:24-30.
  169. Steffenhagen KA, Easterday BC, Galasso GJ. 1976. Evaluation of 6-azauridine and 5-iododeoxyuridine in the treatment of experimental viral infections. J Infect Dis 133:603-612.
  170. Stengel C, Klein D, Egberink H, et al. 2003. Placebo-controlled double-blind treatment study in naturally feline immunodeficiency virus-infected cats using the chemokine receptor inhibitor 1,1’-bis-1,4,8,11-tetraazacyclotetradekan (AMD3100) (abstract). American College of Veterinary Internal Medicine (ACVIM) Forum, Charlotte, NC.
  171. Stiles J. 1995. Treatment of cats with ocular disease attributable to herpesvirus infection: 17 cases (1983-1993). J Am Vet Med Assoc 207:599-603.
  172. Stiles J, Townsend WM, Rogers QR, et al. 2002. Effect of oral administration of L-lysine on conjunctivitis caused by feline herpesvirus in cats. Am J Vet Res 63:99-103.
  173. Straw JA, Loo TL, deVera CC, et al. 1992. Pharmacokinetics of potential anti-AIDS agents thiofoscarnet and foscarnet in the cat. J Acquir Immune Defic Syndr 5:936-942.
  174. Sutton RH, Atwell RB. 1982. Nervous disorders in dogs associated with levamisole therapy. J Small Anim Pract 23:391-397.
  175. Swenson CL, Polas PJ, Cheney CM, et al. 1991. Prophylactic and therapeutic effects of phosphonoformate against feline leukemia virus in vitro. Am J Vet Res 2:2010-2015.
  176. Swenson CL, Sams RA, Polas PJ, et al. 1990. Age-related differences in pharmacokinetics of phosphonoformate in cats. Antimicrob Agents Chemother 34:871-874.
  177. Swenson CL, Weisbrode SE, Nagode LA, et al. 1991. Age-related differences in phosphonoformate-induced bone toxicity in cats. Calcif Tissue Int 48:353-361.
  178. Tanabe T, Yamamoto JK. 2001. Feline immunodeficiency virus lacks sensitivity to the antiviral activity of feline IFN-gamma. J Interferon Cytokine Res 21:1039-1046.
  179. Tankersley RW. 1964. Amino acid requirements of herpes simplex virus in human cells. J Bacteriol 87:609-613.
  180. Tateyama S, Priosoeryanto BP, Yamaguchi R, et al. 1995. In vitro growth inhibition activities of recombinant feline interferon on all lines derived from canine tumours. Res Vet Sci 59:275-277.
  181. Tavares L, Roneker C, Postie L, et al. 1989. Testing of nucleoside analogues in cats infected with feline leukemia virus: a model. Intervirology 30:26-35.
  182. Thanawongnuwech R, Amonsin A, Tantilertcharoen R, et al. 2005. Probable tiger-to-tiger transmission of avian influenza H5N1. Emerg Infect Dis 11: 699-701.
  183. Theilen GH, Hills D. 1982. Comparative aspects of cancer immunotherapy: immunologic methods used for treatment of spontaneous cancer in animals. J Am Vet Med Assoc 181:1134-1141.
  184. Thomasy SM, Maggs DJ, Moulin NK, et al. 2007. Pharmacokinetics and safety of penciclovir following oral administration of famciclovir to cats. Am J Vet Res 68:1252-1258.
  185. Tomkins MB, Cummins JM. 1982. Response of FeLV-induced nonregenerative anemia to oral administration of a bovine interferon-containing preparation. Feline Pract 12:6-15.
  186. Tompkins WA. 1999. Immunomodulation and therapeutic effects of the oral use of interferon-α: mechanism of action. J Interferon Cytokine Res 19:817-828.
  187. Truyen U. 2010. Unpublished observations. University of Leipzig, Leipzig, Germany.
  188. Uckun FM, Chen CL, Samuel P, et al. 2001. In vivo antiretroviral activity of stampidine in chronically feline immunodeficiency virus-infected cats. Antimicrob Agents Chemother 47:1233-1240.
  189. Uchino T, Kano R, Kouzuki S. 1992. Investigations of feline interferon and its therapeutic effects for field use: its therapeutics effects on feline calicivirus infection. Jap J 11:11.
  190. Ueda Y, Sakurai T, Kasama K, et al. 1993. Pharmacokinetic properties of recombinant feline interferon and its stimulatory effect on 2’,5’-oligoadenylate synthetase activity in the cat. J Vet Med Sci 55:1-6.
  191. Ueda Y, Sakurai T, Yanai A. 1993b. Homogeneous production of feline interferon in silkworm by replacing single amino acid code in signal peptide region in recombinant baculovirus and characterization of the product. J Vet Med Sci 55:251-258.
  192. Vandevelde M, Boring JG, Hoff EJ, et al. 1978. The effect of levamisole on the canine central nervous system. J Neuropathol Exp Neurol 37:165-173.
  193. Van der Meulen K, Garré B, Croubels S, et al. 2006. In vitro comparison of antiviral drugs against feline herpesvirus 1. Vet Res 26:13.
  194. Vasco KA, McMichael J, Smith B, et al. 1988. Use of an immunomodulating agent in the treatment of myofascial pain. Vet Rev 8:5.
  195. Weiss RC. 1988. Immunotherapy for feline leukemia, using staphylococcal protein A or heterologous interferons: immunopharmacologic actions and potential use. J Am Vet Med Assoc 192:681-684.
  196. Weiss RC. 1989. Synergistic antiviral activities of acyclovir and recombinant human leukocyte (alpha) interferon on feline herpesvirus replication. Am J Vet Res 50:1672-1677.
  197. Weiss RC. 1995. Treatment of feline infectious peritonitis with immunomodulating agents and antiviral drugs-a review. Feline Pract 23:103-106.
  198. Weiss RC, Cox NR, Boudreaux MK. 1993. Toxicologic effects of ribavirin in cats. J Vet Pharmacol Ther 16:301-316.
  199. Weiss RC, Cox NR, Martinez ML. 1993. Evaluation of free or liposome-encapsulated ribavirin for antiviral therapy of experimentally induced feline infectious peritonitis. Res Vet Sci 55:162-172.
  200. Weiss RC, Cox NR, Oostrom-Ram T. 1990. Effect of interferon or Propionibacterium acnes on the course of experimentally induced feline infectious peritonitis in specific-pathogen-free and random-source cats. Am J Vet Res 51:726-733.
  201. Weiss RC, Cummins JM, Richards AB. 1991. Low-dose orally administered alpha interferon treatment for feline leukemia virus infection. J Am Vet Med Assoc 199:1477-1481.
  202. Weiss RC, Oostrom-Ram T. 1989. Inhibitory effects of ribavirin alone or combined with human alpha interferon on feline infectious peritonitis virus replication in vitro. Vet Microbiol 20:255-265.
  203. Weiss RC, Oostrom-Ram T. 1990. Effect of recombinant human interferon-alpha in vitro and in vivo on mitogen-induced lymphocyte blastogenesis in cats. Vet Immunol Immunopathol 24:147-157.
  204. Wells TN, Proudfoot AE, Power CA, et al. 1996. Chemokine receptors—the new frontier for AIDS research. Chem Biol 3:603-609.
  205. Whitley RJ, Gnann JW. 1992. Acyclovir: a decade later. N Engl J Med 327:782-788.
  206. Wilde H, Khawplod P, Hemachudha T, et al. 2002. Postexposure treatment of rabies infection: can it be done without immunoglobulin? Clin Infect Dis 34:477-480.
  207. Willett BJ, Hosie MJ. 1999. The role of the chemokine receptor CXCR4 in infection with feline immunodeficiency virus. Mol Membr Biol 16:67-72.
  208. Willett BJ, Picard L, Hosie MJ, et al. 1997. Shared usage of the chemokine receptor CXCR4 by the feline and human immunodeficiency viruses. J Virol 71:6407-6415.
  209. Williams DL, Fitzmaurice T, Lay L, et al. 2004. Efficacy of antiviral agents in feline herpetic keratitis: results of an in vitro study. Curr Eye Res 29:215-218.
  210. Woo JC, Dean GA, Lavoy A, et al. 1999. Investigation of recombinant human insulin-like growth factor type I in thymus regeneration in the acute stage of experimental FIV infection in juvenile cats. AIDS Res Hum Retroviruses 15:1377-1388.
  211. Wooley RE, Brown J, Scott TA, et al. 1974. Effect of polyinosinic-polycytidylic acid in dogs experimentally infected with infectious canine hepatitis virus. Am J Vet Res 35:1217-1219.
  212. Wynn SG. 1998. Studies on use of homeopathy in animals. J Am Vet Med Assoc 212:719-724.
  213. Yamauchi K, Wakabayashi H, Hashimoto S, et al. 1998. Effects of orally administered bovine lactoferrin on the immune system of healthy volunteers. Adv Exp Med Biol 443:261-265.
  214. Yates KM, Rosenberg LJ, Harris CK, et al. 1992. Pilot study of the effect of acemannan in cats infected with feline immunodeficiency virus. Vet Immunol Immunopathol 35:177-189.
  215. Zeidner NS, Myles MH, Mathiason-DuBard CK, et al. 1990. Alpha interferon (2b) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome. Antimicrob Agents Chemother 34:1749-1756.
  216. Zeidner NS, Rose LM, Mathiason-DuBard CK, et al. 1990. Zidovudine in combination with alpha interferon and interleukin-2 as prophylactic therapy for FeLV-induced immunodeficiency syndrome (FeLV-FAIDS). J Acquir Immune Defic Syndr 3:787-796.
  217. Zhu Y, Antony JM, Martinez JA, et al. 2007. Didanosine causes sensory neuropathy in an HIV/AIDS animal model: impaired mitochondrial and neurotrophic factor gene expression. Brain 130:2011-2023.
  218. Zhu YQ, Remington KM, North TW. 1996. Mutants of feline immunodeficiency virus resistant to 2’,3’-dideoxy-2’,3’-didehydrothymidine. Antimicrob Agents Chemother 40:1983-1987.
  219. Zimecki M, Artym J, Chodaczek G, et al. 2004. Protective effects of lactoferrin in Escherichia coli-induced bacteremia in mice: relationship to reduced serum TNF alpha level and increased turnover of neutrophils. Inflamm Res 53:292-296.
  220. Zwahlen RD, Spreng D, Wyder-Walther M. 1994. In vitro and in vivo activity of human interleukin-8 in dogs. Vet Pathol 31:61-66.